<DOC>
	<DOCNO>NCT01007942</DOCNO>
	<brief_summary>This phase III , double-blind , placebo-controlled multinational study assess combination everolimus , vinorelbine , trastuzumab compare combination vinorelbine trastuzumab respect progressive-free survival survival HER2/neu positive woman locally advance metastatic breast cancer resistant trastuzumab pre-treated taxane .</brief_summary>
	<brief_title>Daily Everolimus Combination With Trastuzumab Vinorelbine HER2/Neu Positive Women With Locally Advanced Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Histologically cytologically confirm invasive breast carcinoma locally recurrent radiological evidence metastatic disease . Locally recurrent disease must amenable resection curative intent . HER2+ status define IHC 3+ stain situ hybridization positive Patients resistance trastuzumab Prior taxane therapy Patients ECOG performance status 0 2 Patients measurable disease per RECIST criterion Documentation negative pregnancy test patient child bear potential prior enrollment within 7 day prior randomization . Sexually active premenopausal woman must use adequate contraceptive measure , exclude estrogen contain contraceptive , study ; Patients must meet laboratory criterion define study within 21 day prior randomization Prior mTOR inhibitor vinca alkaloid agent treatment cancer More three prior chemotherapy line advance disease . Symptomatic CNS metastases evidence leptomeningeal disease . Previously treat asymptomatic CNS metastasis allow provide last treatment CNS metastases complete &gt; 8 week prior randomization Impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption oral everolimus Peripheral neuropathy â‰¥ grade 2 randomization Active cardiac disease History cardiac dysfunction Any malignancy within 5 year prior randomization , exception adequately treat insitu carcinoma cervix uterus , basal squamous cell carcinoma nonmelanomatous skin cancer Known hypersensitivity study medication Breastfeeding pregnant</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Metastatic breast cancer</keyword>
	<keyword>locally advanced breast cancer</keyword>
	<keyword>HER2/neu positive breast cancer</keyword>
	<keyword>HER2/neu over-expressing</keyword>
	<keyword>progressive-free survival ( PFS )</keyword>
	<keyword>survival ( OS )</keyword>
	<keyword>bolero</keyword>
	<keyword>bolero 3</keyword>
	<keyword>Breast cancer</keyword>
	<keyword>everolimus</keyword>
	<keyword>HER+</keyword>
	<keyword>vinorelbine</keyword>
	<keyword>herceptin</keyword>
	<keyword>trastuzumab</keyword>
	<keyword>RAD001</keyword>
</DOC>